BASSIL MAZEN KUBLAOUI MD
Prescription History 1881654549
Pediatrics - Pediatric Endocrinology in Philadelphia, PA

NPI Status: Active since March 27, 2006

Contact Information

3401 CIVIC CENTER BLVD
CHILDREN'S HOSPITAL OF PHILADELPHIA - ENDOCRINOLOGY
PHILADELPHIA, PA
ZIP 19104
Phone: (215) 590-3174
Fax: (215) 590-3053

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for BASSIL MAZEN KUBLAOUI MD, an active Pediatric Endocrinology specialist practicing in Philadelphia, PA. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 40 documented patient claims. Among these therapy options, the most frequently utilized medication is Estradiol (Twice Weekly), which accounts for 15 claims alone.

Medication Index

No matching medications currently found on file.

Desmopressin Acetate

Generic Formulation: Desmopressin (Nonrefrigerated)Specialty: Endocrinology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
PA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills24.8
Peer Average Days Supply674
Conservative Utilization

This provider writes prescriptions for this formulation 31.6% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,361.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$797.05

State Avg Cost Per Claim

$87.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.

Therapeutic Applications

Desmopressin is used to control the amount of urine your kidneys make. Normally, the amount of urine you make is controlled by a certain substance in the body called vasopressin. In people who have water diabetes (diabetes insipidus) or certain kinds of head injury or brain surgery, the body does not make enough vasopressin. Desmopressin is a man-made form of vasopressin and is used to replace a low level of vasopressin. This medication helps to control increased thirst and too much urination due to these conditions, and helps prevent dehydration. Desmopressin is also used to control bleeding caused by surgery or injuries in people with certain bleeding problems (hemophilia A, type 1 von Willebrand's disease). It works by helping the body with normal blood clotting.

Estradiol (Twice Weekly)

Generic Formulation: EstradiolSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 422
PA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills28.7
Peer Average Days Supply836
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $707.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$47.17

State Avg Cost Per Claim

$107.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Levothyroxine Sodium

Generic Formulation: Levothyroxine SodiumSpecialty: Endocrinology
Provider Metrics Summary
Total Claims 12
30-Day Fills 36.0
Days Supply 1,080
PA State Average Benchmarks
Peer Average Claims171.0
Peer Average 30-Day Fills360.6
Peer Average Days Supply10,486
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 93.0% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $433.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.10

State Avg Cost Per Claim

$16.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.

Therapeutic Applications

Levothyroxine is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally produced by the thyroid gland. Low thyroid hormone levels can occur naturally or when the thyroid gland is injured by radiation/medications or removed by surgery. Having enough thyroid hormone is important for maintaining normal mental and physical activity. In children, having enough thyroid hormone is important for normal mental and physical development. This medication is also used to treat other types of thyroid disorders (such as thyroid cancer). This medication should not be used to treat infertility unless it is caused by low thyroid hormone levels.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like BASSIL MAZEN KUBLAOUI MD provides transparency into local medical care patterns within Philadelphia, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pediatric Endocrinology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.